https://doi.org/10.55788/d9b518a7
Treatments for EoE, which encompass dietary modifications, steroids, and biologics, often fail to fully address the condition [1]. Mepolizumab’s effect on eosinophilic-related inflammation led researchers to explore its potential to improve symptoms of dysphagia and lower oesophageal eosinophil counts in adolescents and adults with active EoE.
From 2018 to 2022, a randomised, double-blind, placebo-controlled trial was conducted across 4 research centres in the US. A total of 66 participants with EoE, aged between 16 and 75 years, received either a 300 mg dose of mepolizumab for 6 months or a placebo. After 3 months, placebo recipients switched to a 100 mg dose of mepolizumab until month 6. The primary outcome was a change in dysphagia from the baseline to month 3, assessed by the Eosinophilic Esophagitis Activity Index (EEsAI).
At month 3, the EEsAI decreased more in the mepolizumab group compared with the placebo group (-15.4 vs -8.3; P=0.14), although this difference did not reach statistical significance. This trend persisted up to the sixth month.
Secondary outcomes demonstrated a promising trend. At month 3, mepolizumab significantly reduced peak eosinophil counts (-77.5 in the mepolizumab group vs 16.7 in the placebo group; P<0.001), leading to a better histological response (<15 eos/hpf in 3% of the placebo group vs 42% in the mepolizumab group; P<0.001). Mepolizumab also reduced endoscopic severity compared with placebo (-1 vs -0.4, respectively; P=0.03). At month 6, the higher dose of mepolizumab showed lower peak eosinophil counts than the 100 mg dose (26.0 ± 19.7 vs 50.2 ± 42.2, respectively; P=0.008), although the histological response remained similar.
In conclusion, mepolizumab emerged as a potential treatment for difficult-to-treat EoE participants. While it did not significantly impact dysphagia symptoms, it improved eosinophil counts and endoscopic severity, suggesting potential use in severe cases. Future studies are needed to determine how best to incorporate this treatment into EoE management strategies.
- Dellon E, et al. Mepolizumab for treatment of adolescents and adults with eosinophilic esophagitis: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Lecture 463, DDW 2023, 6–9 May, Chicago, IL, USA.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Dupilumab improves eosinophilic oesophagitis outcomes, regardless of history of oesophageal dilation Next Article
Terlipressin shows promise for participants with hepatorenal syndrome and concomitant alcoholic hepatitis »
« Dupilumab improves eosinophilic oesophagitis outcomes, regardless of history of oesophageal dilation Next Article
Terlipressin shows promise for participants with hepatorenal syndrome and concomitant alcoholic hepatitis »
Table of Contents: DDW 2023
Featured articles
EVOLVE Expansion study: vedolizumab and ustekinumab as first-line biologic treatments for Crohn’s disease
PIPAC technique shows promise for unresectable colorectal peritoneal metastases
Upper GI Disorders: Hot Topics
Dupilumab improves eosinophilic oesophagitis outcomes, regardless of history of oesophageal dilation
Inflammatory Bowel Disease: Novel Developments
EVOLVE Expansion study: vedolizumab and ustekinumab as first-line biologic treatments for Crohn’s disease
Environmental and dietary factors can amplify paediatric IBD risk
Ulcerative colitis: bowel urgency remission associated with improvement in fatigue
Crohn’s disease: Upadacitinib improves endoscopic outcomes in participants with or without previous biologic failure
Microbiota in GI Diseases
Durability of SER-109 clinical response in patients with recurrent Clostridioides difficile infection
IBS management: the complex role of dietary fibres
Daily and seasonal fluctuations in the gut microbiome
Spotlight on Colorectal Cancer
Colorectal cancer: Aspirin and NSAIDs could reduce the risk of early-onset adenomas
PIPAC technique shows promise for unresectable colorectal peritoneal metastases
What is New in Hepatology?
Terlipressin shows promise for participants with hepatorenal syndrome and concomitant alcoholic hepatitis
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy